Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CPT2 | P23786 | 1/20 | 0.35 |
| ▸ | CPT1A | P50416 | 1/20 | 0.35 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zinc Ion SCHEMBL3338508 | 0.97 | EPHX2 (0.43) | EPHX2CPT2CPT1ACPT1BNOD1 | |
| Zinc Ion SCHEMBL2580359 | 0.96 | EPHX2 (0.42) | EPHX2CPT2CPT1ACPT1BNOD1 | |
| SCHEMBL4425978 | 0.90 | EPHX2 (0.37) | EPHX2NOD1KMT2A | |
| Zinc Ion SCHEMBL2577660 | 0.86 | KMT2A (0.33) | EPHX2NOD1KMT2A | |
| Zinc Ion SCHEMBL2585203 | 0.83 | NMT1 (0.34) | EPHX2NOD1KMT2A | |
| Zinc Ion SCHEMBL2577508 | 0.81 | FOLH1 (0.36) | EPHX2NOD1KMT2A | |
| Zinc Ion SCHEMBL2580310 | 0.81 | SLC6A5 (0.43) | NOD1 | |
| SCHEMBL2152753 | 0.80 | EPHX2 (0.45) | EPHX2CPT2CPT1ACPT1B | |
| Zinc Ion SCHEMBL2574083 | 0.80 | NOD1 (0.44) | EPHX2CPT2CPT1ACPT1BNOD1 | |
| Zinc Ion SCHEMBL2574899 | 0.79 | FNTA (0.46) | EPHX2NOD1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170340603-A1 | COMPOSITIONS AND METHODS FOR SKIN CARE | ANTIPODEAN PHARMACEUTICALS INC (NZ) | 2017-11-30 | — | — | US | claimed |
| US-20260000640-A1 | COMPOSITIONS AND METHODS FOR SKIN CARE | ANTIPODEAN PHARMACEUTICALS INC (NZ) | 2026-01-01 | — | — | US | disclosed |
| US-20190008825-A1 | COMPOSITIONS AND METHODS FOR SKIN CARE | ANTIPODEAN PHARMACEUTICALS INC (NZ) | 2019-01-10 | — | — | US | disclosed |
| US-10085966-B2 | Compositions and methods for skin care | ANTIPODEAN PHARMACEUTICALS, INC. (NZ) | 2018-10-02 | — | — | US | disclosed |
| US-20170340603-A1 | COMPOSITIONS AND METHODS FOR SKIN CARE | ANTIPODEAN PHARMACEUTICALS INC (NZ) | 2017-11-30 | — | — | US | disclosed |
| EP-2271349-B1 | COMPOSITIONS AND METHODS FOR SKIN CARE | ANTIPODEAN PHARMACEUTICALS INC (NZ) | 2017-03-15 | — | — | EP | disclosed |
| US-20100152288-A1 | NOVEL a-LIPOIC ACID DERIVATIVES AND APPLICATIONS THEREOF | SENJU PHARMACEUTICAL CO. LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-7700080-B2 | Method of suppressing melanin production by metal chelates of lipoyl amino acid derivatives | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2010-04-20 | — | — | US | disclosed |
| WO-2009145982-A1 | COMPOSITIONS AND METHODS FOR SKIN CARE | ANTIPODEAN PHARMACEUTICALS, INC. (NZ) | 2009-12-03 | — | — | WO | disclosed |
| EP-1371640-B1 | NOVEL A-LIPOIC ACID DERIVATIVE AND USE THEREOF | SENJU PHARMA CO (JP) | 2009-10-28 | — | — | EP | disclosed |
| US-20090258841-A1 | COMPOSITIONS AND METHODS FOR SKIN CARE | ANTIPODEAN PHARMACEUTICALS, INC. (NZ) | 2009-10-15 | — | — | US | disclosed |
| US-20040092586-A1 | Novel a-lipoic acid derivative and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | US | disclosed |
| EP-1371640-A1 | NOVEL A-LIPOIC ACID DERIVATIVE AND USE THEREOF | Senju Pharmaceutical Co., Ltd. (JP) | 2003-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000640-A1 | COMPOSITIONS AND METHODS FOR SKIN CARE | TXN2, NDUFA2, NDUFA9 | EPHX2 1522/4885CPT2 96/4885CPT1A 477/4885 |
| US-20100152288-A1 | NOVEL a-LIPOIC ACID DERIVATIVES AND APPLICATIONS THEREOF | TYR, SERPINB1, LPO | EPHX2 1159/4885CPT2 2989/4885CPT1A 1308/4885 |
| US-10085966-B2 | Compositions and methods for skin care | TFAM, HSPA9, MT-CO3 | EPHX2 3242/4885CPT2 38/4885CPT1A 232/4885 |
| US-20090258841-A1 | COMPOSITIONS AND METHODS FOR SKIN CARE | TFAM, HSPA9, MT-CO3 | EPHX2 3242/4885CPT2 38/4885CPT1A 232/4885 |
| US-20040092586-A1 | Novel a-lipoic acid derivative and use thereof | TYR, SERPINB1, LPO | EPHX2 1812/4885CPT2 3362/4885CPT1A 1029/4885 |
| US-20190008825-A1 | COMPOSITIONS AND METHODS FOR SKIN CARE | TFAM, HSPA9, MT-CO3 | EPHX2 3242/4885CPT2 38/4885CPT1A 232/4885 |
| US-20170340603-A1 | COMPOSITIONS AND METHODS FOR SKIN CARE | TFAM, HSPA9, MT-CO3 | EPHX2 3242/4885CPT2 38/4885CPT1A 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.